Suppr超能文献

内镜和外路泪囊鼻腔吻合术:治疗获得性远端泪道阻塞的一种治疗方案。

Endoscopic and external dacryocystorhinostomy: A therapeutic proposal for distal acquired lacrimal obstructions.

机构信息

Division of Head and Neck Department, Otorhinolaryngology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.

出版信息

Eur J Ophthalmol. 2023 May;33(3):1287-1293. doi: 10.1177/11206721221132746. Epub 2022 Oct 17.

Abstract

Endoscopic (END-DCR) and external dacryocystorhinostomies (EXT-DCR) are nowadays considered the gold standard techniques for non-oncologic distal acquired lacrimal disorders (DALO). However, no unanimous consensus has been achieved on which of these surgeries is the most suitable to the individual patient. Herein, we review the available literature of the last 30 years with the aim of defining a simple and reproduceable treatment algorithm to treat DALO. A search of PubMed, EMBASE, Scopus and Cochrane databases was last performed in December 2021 to examine evidence regarding the role of END-DCR and EXT-DCR in primary and revision surgeries. If considered primary surgeries, END-DCR should be preferred in case of intranasal comorbidities, given the possibility to directly visualize and treat potential intranasal pathologies. Conversely, EXT-DCR should be chosen in case of need/preference for local anesthesia, given the major historical experience and wider surgical field that helps to resolve intra-operatory complications (e.g., bleeding) in an uncollaborative patient. In the absence of the abovementioned conditions, the decision of one or other approach should be discussed with the patient. In recurrent cases, END-DCR should be considered the treatment of choice given the major likelihood to visualize the causes of primary failure and directly resolve it. In conclusion, END-DCR should be considered the treatment of choice in revision cases or in primary ones associated with intranasal pathologies, whereas EXT-DCR should be chosen if local anesthesia is needed. In the absence of these scenarios, it is still open to debate which of these two approaches should be used.

摘要

内镜下(END-DCR)和外路(EXT-DCR)鼻泪管造口术目前被认为是非肿瘤性获得性下泪道疾病(DALO)的金标准治疗方法。然而,对于这两种手术哪种最适合个别患者,尚未达成一致共识。本文回顾了过去 30 年的文献,旨在制定一种简单且可重复的治疗方案来治疗 DALO。最后一次在 2021 年 12 月对 PubMed、EMBASE、Scopus 和 Cochrane 数据库进行了搜索,以检查关于 END-DCR 和 EXT-DCR 在原发性和翻修手术中的作用的证据。如果认为是原发性手术,由于可以直接观察和治疗潜在的鼻内病变,因此在存在鼻内合并症的情况下,应优先选择 END-DCR。相反,如果需要/偏好局部麻醉,应选择 EXT-DCR,因为其具有广泛的手术视野,有助于解决协作性差的患者术中的并发症(例如出血)。在不存在上述情况的情况下,应与患者讨论选择一种或另一种方法。在复发性病例中,由于极有可能观察到原发性失败的原因并直接解决,因此应将 END-DCR 视为首选治疗方法。总之,在翻修病例或与鼻内病变相关的原发性病例中,应考虑使用 END-DCR;如果需要局部麻醉,则应选择 EXT-DCR。在不存在这些情况的情况下,这两种方法中哪一种更适用仍存在争议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f83/10152216/4e9c2d8110dd/10.1177_11206721221132746-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验